Group 1 - The company plans to globally offer 36.56 million shares, with 3.66 million shares available in Hong Kong and 32.90 million shares for international offering, along with an over-allotment option of 5.48 million shares [1] - The subscription period is from August 7 to August 12, with a maximum offer price of HKD 18.68 per share, and an entry fee of approximately HKD 3,773.68 for a board lot of 200 shares [1] - The total expected fundraising amount is HKD 683 million, with a net amount of HKD 610 million, which will be used for ongoing and planned clinical trials, commercialization of the core product, and general corporate purposes [1] Group 2 - The company is the first in Asia and the third globally to commercialize a novel human long-acting glucagon-like peptide-1 (GLP-1) receptor agonist [2] - The core product, Isu-Paglutide α (brand name: Yinuo Qing), is already commercialized in China for the treatment of type 2 diabetes (T2D) [2] - The company reported net losses of CNY 301 million, CNY 733 million, and CNY 175 million for the years ending December 31 for 2022, 2023, and 2024, respectively [2]
银诺医药-B(02591.HK) 8月7日起招股